[ad_1]

Free Whitepaper

Direct-to-Patient: Transforming medical trial logistics in a post-Covid world

The Covid-19 pandemic has modified most areas of life, and medical trials had been no exception. Direct-to-patient deliveries are actually a key a part of medical trial logistics and are anticipated to stay necessary even in a post-Covid world.

Choosing the precise logistics accomplice turns what may very well be a posh operation into an environment friendly, simple course of. A superb logistics operator delivers provides to the affected person in a well timed method and in temperature-controlled circumstances. Download this whitepaper to seek out out extra about DtP necessities and why you possibly can depend on main medical trial logistics supplier CRYOPDP to ship your temperature-controlled provides to sufferers.

by CRYOPDP

Enter your particulars right here to obtain your free Whitepaper.

Country
United Kingdom
United States
Afghanistan
Åland Islands
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica
Antigua and Barbuda
Argentina
Armenia
Aruba
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia
Bosnia and Herzegovina
Botswana
Bouvet Island
Brazil
British Indian Ocean Territory
Brunei Darussalam
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Cape Verde
Cayman Islands
Central African Republic
Chad
Chile
China
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Congo
Congo, The Democratic Republic of
The
Cook Islands
Costa Rica
Cote D”ivoire
Croatia
Cuba
Cyprus
Czech Republic
Denmark
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland Islands (Malvinas)
Faroe Islands
Fiji
Finland
France
French Guiana
French Polynesia
French Southern Territories
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guernsey
Guinea
Guinea-bissau
Guyana
Haiti
Heard Island and Mcdonald Islands

Holy See (Vatican City State)
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran, Islamic Republic of
Iraq
Ireland
Isle of Man
Israel
Italy
Jamaica
Japan
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Korea, Democratic People”s
Republic of
Korea, Republic of
Kuwait
Kyrgyzstan
Lao People”s Democratic Republic

Latvia
Lebanon
Lesotho
Liberia
Libyan Arab Jamahiriya
Liechtenstein
Lithuania
Luxembourg
Macao
Macedonia, The Former
Yugoslav Republic of
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mayotte
Mexico
Micronesia, Federated States of
Moldova, Republic of
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
Netherlands Antilles
New Caledonia
New Zealand
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestinian Territory, Occupied
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn
Poland
Portugal
Puerto Rico
Qatar
Reunion
Romania
Russian Federation
Rwanda
Saint Helena
Saint Kitts and Nevis
Saint Lucia
Saint Pierre and Miquelon
Saint Vincent and The Grenadines

Samoa
San Marino
Sao Tome and Principe
Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Singapore
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Georgia and The South
Sandwich Islands
Spain
Sri Lanka
Sudan
Suriname
Svalbard and Jan Mayen
Swaziland
Sweden
Switzerland
Syrian Arab Republic
Taiwan, Province of China
Tajikistan
Tanzania, United Republic of
Thailand
Timor-leste
Togo
Tokelau
Tonga
Trinidad and Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
Uganda
Ukraine
United Arab Emirates
United States Minor Outlying
Islands
Uruguay
Uzbekistan
Vanuatu
Venezuela
Viet Nam
Virgin Islands, British
Virgin Islands, U.S.
Wallis and Futuna
Western Sahara
Yemen
Zambia
Zimbabwe

Validation is Required

Download free Whitepaper

By clicking the Download Free Whitepaper button, you settle for the terms and conditions and acknowledge that your knowledge might be used as described within the CRYOPDP privateness coverage

By downloading this Whitepaper, you acknowledge that we could share your info with our white paper companions/sponsors who could contact you instantly with info on their services.

Visit our privacy policy for extra details about our companies, how we could use, course of and share your private knowledge, together with info in your rights in respect of your private knowledge and how one can unsubscribe from future advertising and marketing communications. Our companies are supposed for company subscribers and also you warrant that the e-mail handle submitted is your company e mail handle.

Thank you.Please test your e mail to obtain the Whitepaper.

One service supplier well-positioned to satisfy these wants is CRYOPDP, which supplies temperature-controlled logistics for the pharmaceutical, biopharmaceutical and medical trial communities. With 24 services throughout 14 nations and a wider community that spans greater than 150 nations, CRYOPDP has the worldwide wants of the life science business lined. And behind all of it is a robust concentrate on high quality service, says the group’s chief working officer Tangi Tremorin:

“When you might be coping with sufferers’ lives, you don’t have any room for errors. It’s all about high quality service, ensuring we distribute the merchandise not solely on time however inside the precise specs, on the proper temperature. The majority of the medical trial firms that we work with are actually world. Clinical trials can typically be in 20-plus nations. Providing the identical high quality service in all places, in each a part of the world, is basically important for the pharma market.”

Quality service, around the globe

A sturdy high quality administration system (QMS) underpins this dedication by centralising all procedures and guaranteeing the identical high quality service is delivered not solely from CRYOPDP’s personal places of work and driving fleet however these of its service companions, too. 

“We choose and qualify them by means of our QMS with thorough analysis processes managed by the standard division. Once we’ve certified them as a service accomplice we offer particular coaching with SOPs and thru our transport administration system after which monitor very intently the standard of the service,” explains Tremorin. 

Proving that dedication like this actually does repay, Tremorin mentions the corporate’s 99.96% world service high quality ranking, which incorporates each CRYOPDP and its companions. The similar duty is taken for any service accomplished by CRYOPDP as its service companions, he provides. 

Driving this service excellence is the corporate’s sturdy sense of mission, which Karine Gradziel, Chief Commercial Officer at CRYOPDP, describes as “to help in enhancing the well being of individuals around the globe and saving the lives of sufferers.” To obtain that mission, CRYOPDP strives to continuously strengthen its world footprint, notably within the markets the place there’s a rising want for pharmaceutical logistics. 

Europe and the US

A big quantity of pharmaceutical R&D is concentrated in Central Europe. According to OECD knowledge, the pharmaceutical business spent roughly $20.1bn on R&D throughout EU nations in 2016.  

This focus can also be mirrored within the sturdy medical trials markets of nations like Germany, the UK, France, Spain, the Netherlands, Italy, and Belgium – the highest seven nations within the WHO’s record of medical trials by nation. As of March 2022, GlobalInformation figures present there are greater than 2,000 medical trials ongoing in Belgium, and in 2017 the small nation accounted for 19% of Europe’s oncology trials.

In May 2021, CRYOPDP introduced the acquisition of F-airGate, a temperature-controlled provide chain options firm positioned proper within the coronary heart of Europe: Brussels. CRYOPDP’s acquisition of the Belgian firm enhances its already sturdy footprint within the UK, France, Poland, Germany, and the Netherlands, serving to it to entry totally different geographies by means of its expansive community of services. With research projecting the European medical trials market to develop at a CAGR of 4.2% between 2018-2026, CRYOPDP is happy to help this increasing market, enhancing illness outcomes for sufferers throughout the continent.

Meanwhile, throughout the Atlantic, CRYOPDP can also be stepping up its service providing within the US. US-based pharmaceutical firms proceed to drive the life science business’s progress. The nation’s pharmaceutical sector grew from $305bn in 2011 to $377bn in 2019. By 2025, GlobalInformation forecasts it to succeed in a worth of $441bn. CRYOPDP is at the moment focusing on a variety of funding in direction of this area and is experiencing quick progress within the US because of this. 

In explicit, cell and gene therapies have develop into a key focus of the US sector and is an space that CRYOPDP is able to serve with high-quality temperature-controlled logistics. Through the reliability of its companies, CRYOPDP is poised to assist US pharma firms overcome the challenges of the cell and gene provide chain.

Growing markets in Asia-Pacific

But gone are the times when Europe and the US had been the world’s solely hubs for all times science exercise. Today, slightly below half of all world medical trials happen in Asia-Pacific. As the biotech market in APAC thrives, CRYOPDP is ensuring it could meet the area’s quickly rising demand for its companies. 

Along with its sister firm Cryoport System, CRYOPDP just lately opened a brand new facility in Singapore. This adopted the launch of the primary collectively operated Global Logistics Center in Osaka, Japan, in 2020 – one other step within the group’s technique to strengthen its APAC footprint.

Within Asia-Pacific, one market rising steadily on the medical trials aspect (and with nice pharmaceutical progress potential) is Australia. Between 2012 and 2021, the variety of medical trials initiated in Australia grew at a rise of 40.48% based on GlobalInformation figures, with oncology a number one remedy space. Noticing this potential, 2021 additionally noticed CRYOPDP purchase an Australian market chief in premium healthcare logistics administration companies: Critical Transport Solutions Australia. 

With two new websites in main cities Sydney and Melbourne, CRYOPDP’s acquisition of this firm helps it to handle the elevated medical trial exercise in Asia-Pacific. The firm is now nicely on monitor to develop into a prime participant within the Australian market. 

From strategic places to quick positioning in key markets, it’s all a part of CRYOPDP’s intention to raised accomplish its mission by aligning with firms that share its mindset. “It’s the individuals; all the time the individuals,” Gradziel provides. “The extra world we’re getting, the extra thrilling it will get as a result of we’re pondering world however as a unit. We work for one another, we assist one another, we push one another to be higher.” 

To study extra concerning the firm, obtain the infographic beneath.

Free Whitepaper

Direct-to-Patient: Transforming medical trial logistics in a post-Covid world

The Covid-19 pandemic has modified most areas of life, and medical trials had been no exception. Direct-to-patient deliveries are actually a key a part of medical trial logistics and are anticipated to stay necessary even in a post-Covid world.

Choosing the precise logistics accomplice turns what may very well be a posh operation into an environment friendly, simple course of. A superb logistics operator delivers provides to the affected person in a well timed method and in temperature-controlled circumstances. Download this whitepaper to seek out out extra about DtP necessities and why you possibly can depend on main medical trial logistics supplier CRYOPDP to ship your temperature-controlled provides to sufferers.

by CRYOPDP

Enter your particulars right here to obtain your free Whitepaper.

Country
United Kingdom
United States
Afghanistan
Åland Islands
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica
Antigua and Barbuda
Argentina
Armenia
Aruba
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia
Bosnia and Herzegovina
Botswana
Bouvet Island
Brazil
British Indian Ocean Territory
Brunei Darussalam
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Cape Verde
Cayman Islands
Central African Republic
Chad
Chile
China
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Congo
Congo, The Democratic Republic of
The
Cook Islands
Costa Rica
Cote D”ivoire
Croatia
Cuba
Cyprus
Czech Republic
Denmark
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland Islands (Malvinas)
Faroe Islands
Fiji
Finland
France
French Guiana
French Polynesia
French Southern Territories
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guernsey
Guinea
Guinea-bissau
Guyana
Haiti
Heard Island and Mcdonald Islands

Holy See (Vatican City State)
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran, Islamic Republic of
Iraq
Ireland
Isle of Man
Israel
Italy
Jamaica
Japan
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Korea, Democratic People”s
Republic of
Korea, Republic of
Kuwait
Kyrgyzstan
Lao People”s Democratic Republic

Latvia
Lebanon
Lesotho
Liberia
Libyan Arab Jamahiriya
Liechtenstein
Lithuania
Luxembourg
Macao
Macedonia, The Former
Yugoslav Republic of
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mayotte
Mexico
Micronesia, Federated States of
Moldova, Republic of
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
Netherlands Antilles
New Caledonia
New Zealand
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestinian Territory, Occupied
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn
Poland
Portugal
Puerto Rico
Qatar
Reunion
Romania
Russian Federation
Rwanda
Saint Helena
Saint Kitts and Nevis
Saint Lucia
Saint Pierre and Miquelon
Saint Vincent and The Grenadines

Samoa
San Marino
Sao Tome and Principe
Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Singapore
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Georgia and The South
Sandwich Islands
Spain
Sri Lanka
Sudan
Suriname
Svalbard and Jan Mayen
Swaziland
Sweden
Switzerland
Syrian Arab Republic
Taiwan, Province of China
Tajikistan
Tanzania, United Republic of
Thailand
Timor-leste
Togo
Tokelau
Tonga
Trinidad and Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
Uganda
Ukraine
United Arab Emirates
United States Minor Outlying
Islands
Uruguay
Uzbekistan
Vanuatu
Venezuela
Viet Nam
Virgin Islands, British
Virgin Islands, U.S.
Wallis and Futuna
Western Sahara
Yemen
Zambia
Zimbabwe

Validation is Required

Download free Whitepaper

By clicking the Download Free Whitepaper button, you settle for the terms and conditions and acknowledge that your knowledge might be used as described within the CRYOPDP privateness coverage

By downloading this Whitepaper, you acknowledge that we could share your info with our white paper companions/sponsors who could contact you instantly with info on their services.

Visit our privacy policy for extra details about our companies, how we could use, course of and share your private knowledge, together with info in your rights in respect of your private knowledge and how one can unsubscribe from future advertising and marketing communications. Our companies are supposed for company subscribers and also you warrant that the e-mail handle submitted is your company e mail handle.

Thank you.Please test your e mail to obtain the Whitepaper.

[ad_2]

Source link

#Navigating #pharmas #globalisation #worldwide #healthcare #temperaturecontrolled #logistics

By Seth A. Dunbar

Seth Dunbar leads clinical research study operations and quality & compliance. He is experienced working with teams to help drug sponsors better leverage eSource data. With 10+ years of experience Seth brings expertise developing eClinical services that integrate data and technology to help companies optimise study execution.

Leave a Reply

Your email address will not be published. Required fields are marked *